Replication-defective adenoviruses comprising nucleic acids encoding SARS-CoV-2 s glycoprotein and modified N protein comprising an endosomal targeting sequence
US11684668B2 · kind B2 · utility
0Cited by
10References
16Claims
0Family size
Assignee
Inventor
Key dates
| Filing date | May 26, 2020 |
| Grant date | Jun 27, 2023 |
| Priority date | — |
| Expiry date | May 26, 2040 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12Y304/17023
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Compositions and methods are presented for prevention and/or treatment of a coronavirus disease wherein the composition comprises a recombinant entity. The recombinant entity comprises a nucleic acid that encodes a nucleocapsid protein of coronavirus 2 (CoV2); and/or wherein the recombinant entity encodes a spike protein of CoV2.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.